Literature DB >> 19280268

Expression of cytokine signaling genes in morbidly obese patients with non-alcoholic steatohepatitis and hepatic fibrosis.

J Michael Estep1, Ancha Baranova, Noreen Hossain, Hazem Elariny, Kathy Ankrah, Arian Afendy, Vikas Chandhoke, Zobair M Younossi.   

Abstract

BACKGROUND: White adipose tissue (WAT) from visceral adiposity plays an important role in the pathogenesis of non-alcoholic steatohepatitis (NASH). Development of NASH and its progression to fibrosis is partially due to cytokines and adipokines produced by WAT. The aim of this study was to assess the association of hepatic fibrosis and NASH by evaluating the intrinsic differences in the inflammatory cytokine signaling in the visceral adipose tissue obtained from morbidly obese patients.
METHODS: We used targeted microarrays representing human genes involved in the inflammatory and fibrogenic reactions to profile visceral adipose samples of 15 well-matched NASH patients with and without fibrosis. Additionally, visceral adipose samples were subjected to real-time polymerase chain reaction profiling of 84 inflammations related genes.
RESULTS: Eight genes (CCL2, CCL4, CCL18, CCR1, IL10RB, IL15RA, and LTB) were differentially expressed in NASH with fibrosis. Additionally, an overlapping but distinct list of the differentially expressed genes were found in NASH with type II diabetes (DM; IL8, BLR1, IL2RA, CD40LG, IL1RN, IL15RA, and CCL4) as compared to NASH without DM.
CONCLUSIONS: Inflammatory cytokines are differentially expressed in the adipose tissue of NASH with fibrosis, as well in NASH with DM. These findings point at the interaction of adipose inflammatory cytokines, DM, hepatic fibrosis in NASH, and its progression to cirrhosis and end-stage liver disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19280268     DOI: 10.1007/s11695-009-9814-x

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  24 in total

1.  Regulation of monocyte chemoattractant protein 1 (MCP-1) release by explants of human visceral adipose tissue.

Authors:  J N Fain; A K Madan
Journal:  Int J Obes (Lond)       Date:  2005-11       Impact factor: 5.095

2.  Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control.

Authors:  F Cipollone; F Chiarelli; G Davì; C Ferri; G Desideri; M Fazia; A Iezzi; F Santilli; B Pini; C Cuccurullo; S Tumini; A Del Ponte; A Santucci; F Cuccurullo; A Mezzetti
Journal:  Diabetologia       Date:  2005-05-03       Impact factor: 10.122

3.  Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression.

Authors:  Keishi Kanno; Susumu Tazuma; Tomoji Nishioka; Hideyuki Hyogo; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

4.  Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance.

Authors:  Ancha Baranova; Shobha J Gowder; Karen Schlauch; Hazem Elariny; Rochelle Collantes; Arian Afendy; Janus P Ong; Zachary Goodman; Vikas Chandhoke; Zobair M Younossi
Journal:  Obes Surg       Date:  2006-09       Impact factor: 4.129

5.  Usefulness of serum hepatic fibrosis markers in the diagnosis of nonalcoholic steatohepatitis (NASH).

Authors:  Nozomi Sasaki; Takato Ueno; Yasuyo Morita; Eisuke Nagata; Michio Sata
Journal:  Hepatogastroenterology       Date:  2006 Sep-Oct

Review 6.  History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells.

Authors:  A Geerts
Journal:  Semin Liver Dis       Date:  2001-08       Impact factor: 6.115

7.  Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation.

Authors:  M D Weltman; G C Farrell; C Liddle
Journal:  Gastroenterology       Date:  1996-12       Impact factor: 22.682

8.  Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease.

Authors:  Ancha Baranova; Karen Schlauch; Hazem Elariny; Mohammed Jarrar; Chase Bennett; Clare Nugent; Shobha J Gowder; Zahra Younoszai; Rochelle Collantes; Vikas Chandhoke; Zobair M Younossi
Journal:  Obes Surg       Date:  2007-08       Impact factor: 4.129

9.  Visceral fat adipokine secretion is associated with systemic inflammation in obese humans.

Authors:  Luigi Fontana; J Christopher Eagon; Maria E Trujillo; Philipp E Scherer; Samuel Klein
Journal:  Diabetes       Date:  2007-02-07       Impact factor: 9.461

Review 10.  Chronic inflammation: role of adipose tissue and modulation by weight loss.

Authors:  Tongjian You; Barbara J Nicklas
Journal:  Curr Diabetes Rev       Date:  2006-02
View more
  22 in total

1.  Pro- and anti-inflammatory cytokines in steatosis and steatohepatitis.

Authors:  Fabiola Rabelo; Claudia P M S Oliveira; Joel Faintuch; Daniel F C Mazo; Vicencia M R Lima; Jose Tadeu Stefano; Hermes V Barbeiro; Francisco G Soriano; Venancio A Ferreira Alves; Flair J Carrilho
Journal:  Obes Surg       Date:  2010-07       Impact factor: 4.129

2.  Treatment options for nonalcoholic fatty liver disease.

Authors:  Brian Lam; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

3.  Pro-atherosclerotic markers and cardiovascular risk factors one year after liver transplantation.

Authors:  Mario Reis Alvares-da-Silva; Claudia Pinto Marques Souza de Oliveira; José Tadeu Stefano; Hermes V Barbeiro; Denise Barbeiro; Francisco G Soriano; Alberto Queiroz Farias; Flair José Carrilho; Luiz Augusto Carneiro D'Albuquerque
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

4.  Krüppel-like factor 4 regulates macrophage polarization.

Authors:  Xudong Liao; Nikunj Sharma; Fehmida Kapadia; Guangjin Zhou; Yuan Lu; Hong Hong; Kaavya Paruchuri; Ganapati H Mahabeleshwar; Elise Dalmas; Nicolas Venteclef; Chris A Flask; Julian Kim; Bryan W Doreian; Kurt Q Lu; Klaus H Kaestner; Anne Hamik; Karine Clément; Mukesh K Jain
Journal:  J Clin Invest       Date:  2011-06-13       Impact factor: 14.808

Review 5.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

Review 6.  The relationship between oxidative stress and nonalcoholic fatty liver disease: Its effects on the development of nonalcoholic steatohepatitis.

Authors:  Fatma Ucar; Sevilay Sezer; Serpil Erdogan; Sumeyya Akyol; Ferah Armutcu; Omer Akyol
Journal:  Redox Rep       Date:  2013-06-05       Impact factor: 4.412

7.  Liver and diabetes. A vicious circle.

Authors:  Paola Loria; Amedeo Lonardo; Frank Anania
Journal:  Hepatol Res       Date:  2013-01       Impact factor: 4.288

8.  Quercetin improves insulin resistance and hepatic lipid accumulation in vitro in a NAFLD cell model.

Authors:  Xiuli Li; Rong Wang; Na Zhou; Xiaohui Wang; Qingyan Liu; Yuqin Bai; Yin Bai; Zhijie Liu; Huiming Yang; Jihong Zou; Hongxia Wang; Tiewei Shi
Journal:  Biomed Rep       Date:  2012-10-22

9.  Expression of inflammation-related genes is altered in gastric tissue of patients with advanced stages of NAFLD.

Authors:  Rohini Mehta; Aybike Birerdinc; Arpan Neupane; Amirhossein Shamsaddini; Arian Afendy; Hazem Elariny; Vikas Chandhoke; Ancha Baranova; Zobair M Younossi
Journal:  Mediators Inflamm       Date:  2013-03-30       Impact factor: 4.711

10.  Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS).

Authors:  Ancha Baranova; Thuy Phuong Tran; Arian Afendy; Lei Wang; Amirhossein Shamsaddini; Rohini Mehta; Vikas Chandhoke; Aybike Birerdinc; Zobair M Younossi
Journal:  J Transl Med       Date:  2013-05-31       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.